BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3156770)

  • 1. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.
    Monroe SE; Henzl MR; Martin MC; Schriock E; Lewis V; Nerenberg C; Jaffe RB
    Fertil Steril; 1985 Mar; 43(3):361-8. PubMed ID: 3156770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulation inhibition with nafarelin acetate nasal administration for six months.
    Brenner PF; Shoupe D; Mishell DR
    Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
    Sheehan KL; Casper RF; Yen SS
    Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).
    Schriock ED; Monroe SE; Martin MC; Henzl MR; Jaffe RB
    Fertil Steril; 1985 Jun; 43(6):844-50. PubMed ID: 3158549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
    Skarin G; Nillius SJ; Wide L
    Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypersensitivity of the human gonadotrophs to the repeated administration of small doses of LH-RH.
    Faure N; Olivier GC
    Horm Res; 1978; 9(1):12-21. PubMed ID: 338460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
    Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
    Gudmundsson JA; Nillius SJ; Bergquist C
    Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin, estrogen and progesterone response to long term gonadotropin-releasing hormone infusion at various stages of the menstrual cycle.
    Jewelewicz R; Dyrenfurth I; Ferin M; Bogumil J; Vande Wiele RL
    J Clin Endocrinol Metab; 1977 Oct; 45(4):662-7. PubMed ID: 334788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
    Grimes EM; Thompson IE; Taymor ML
    Acta Endocrinol (Copenh); 1975 Aug; 79(4):625-34. PubMed ID: 1098349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of LH release with synthetic LH-RH (author's transl)].
    Koyama T
    Nihon Naibunpi Gakkai Zasshi; 1976 Sep; 52(9):881-97. PubMed ID: 828583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
    Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
    Bouchard P; Wolf JP; Hajri S
    Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.